Johnson & Johnsonvs.Pfizer
JNJ vs PFE · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 3.9× larger than Pfizer by market cap; Johnson & Johnson trades at the lower P/E (29.0 vs 36.3); year to date, Johnson & Johnson leads (+24.9% vs +12.4%).
Side by side
| JNJ | PFE | |
|---|---|---|
| Market cap | $610B | $157B |
| Price | $256.48 | $27.82 |
| Today | −0.8% | −0.6% |
| Return YTD | +24.9% | +12.4% |
| Return 1Y | +36.8% | +6.6% |
| Since June 26, 2026 | +0.7% | +14.5% |
| P/E | 29.0 | 36.3 |
| P/S | 6.2 | 2.5 |
| P/B | 7.2 | 1.8 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Johnson & JohnsonJNJ
Two businesses under one name: Innovative Medicine, which covers immunology and oncology drugs, and MedTech, which makes medical devices and surgical equipment.
Full JNJ profile →PfizerPFE
Vaccines are what most people associate with Pfizer. The portfolio is considerably broader: oncology is a large part of it, and internal medicine covers much of the rest.
Full PFE profile →More JNJ & PFE comparisons
Other head-to-heads in the Big pharma segment.